Free-Circulating DNA in Patients with Chronic Heart Failure
The purpose of this work was to study the significance of the level of free-circulating DNA (fсDNA) in verifying the diagnosis of chronic heart failure (CHF), and to analyze the possible influence of the left ventricular ejection fraction value and biochemical blood test parameters on the studied marker. Materials and methods. The study involved 107 people with CHF who were under the follow-up of a cardiologist. The comparison group (the control one) consisted of 74 people of the same age and gender without chronic pathology. All patients underwent laboratory (clinical, biochemical blood tests) and instrumental examination (electrocardiography, echocardiography, ultrasound examination of the abdominal organs, chest radiography). To assess exercise tolerance, patients took a 6-minute walking test. The concentration of fcDNA in the blood plasma in patients with CHF was determined according to the method proposed by Laktionov P.P., Tamkovich S.N. and Rykova E.Yu. (2005). Results. Values of fсDNA for diagnosing CHF were calculated to be 61–90 ng/ml, and this indicator demonstrated the “excellent” quality of the distribution model according to the ROC curve. In addition, the biomarker is inversely proportional to the value of the ejection fraction, that is, a decrease in myocardial contractility is accompanied by an increase in fcDNA in the blood. A direct correlation of fcDNA with the level of uric acid was found, which is associated with the characteristics of the metabolism of purine bases. Conclusion. The level of fcDNA in blood plasma is characterized by sufficient diagnostic value and can be used as an objective biomarker of the severity of structural disorders in patients with CHF.
Kolesnikova E.V., Myachina O.V., Pashkov A.N. 2024. Free-Circulating DNA in Patients with Chronic Heart Failure. Challenges in Modern Medicine, 47(4): 439–448 (in Russian). DOI: 10.52575/2687-0940-2024-47-4-439-448
While nobody left any comments to this publication.
You can be first.
Belenkov Ju.N., Mareev V.Ju., Ageev F.T., Fomin I.V., Badin Ju.V., Poljakov D.S. 2011. True Prevalence of CHF in the European Part of the Russian Federation (Hospital Stage). Heart Failure. 12(64): 63–68 (in Russian).
Bojcov S.A. 2022. Chronic Heart Failure: Evolution of Etiology, Prevalence and Mortality over the Past 20 Years. Terapevticheskij arhiv. 94(1): 5–8 (in Russian).
Drapkina O.M., Palatkina L.O. 2014. New Emphasis in the Study of the Pathogenesis of Chronic Heart Failure with Preserved Ejection Fraction: Focus on Inflammatory Markers. Rational Pharmacotherapy in Cardiology. 10(3): 317–321 (in Russian).
Kozhevnikova M.V., Belenkov Ju.N. 2021. Biomarkers of Heart Failure: Present and Future. Cardiology. 61(5): 4–16 (in Russian).
Konradi A.O. 2022. Biomarkers, Their Types and Basis for Use in Personalized Medicine. Russian Journal for Personalized Medicine. 2(3): 6–16 (in Russian).
Lipatov I.A., Buksha I.A. 2021. Pathochemical Processes in Gout. Bulletin CSU. Education and Healthcare. 4(16): 67–74 (in Russian).
Oshhepkova E.V, Lazareva N.V., Satlykova D.F., Tereshhenko S.N. 2015. First Results of the Russian Register of Chronic Heart Failure. Cardiology. 55(5): 22–28 (in Russian).
Poljakov D.S., Fomin I.V., Belenkov Ju.N., Mareev V.Ju., Ageev F.T., Artem'eva E.G., Badin Ju.V., Bakulina E.V., Vinogradova N.G., Galjavich A.S., Ionova T.S., Kamalov G.M., Kechedzhieva S.G., Koziolova N.A., Malenkova V.Ju., Mal'chikova S.V., Mareev Ju.V., Smirnova E.A., Tarlovskaja E.I., Shherbinina E.V., Jakushin S.S. 2021. Chronic Heart Failure in the Russian Federation: What Has Changed Over 20 Years of Observation? Results of the EPOCHA-CHF Study. Cardiology. 61(4): 4–14 (in Russian).
Trofimova E.A., Kireeva V.V., Usol'cev Ju.K., Kiril'chik S.V., Lepehova S.A., Aparcin K.A. 2022. Free Circulating DNA in Hypertensive Patients with High Cardiovascular Risk. Russian Journal of Cardiology. 27(4): 4709 (in Russian).
Borlaug B.A. 2020. Evaluation and Management of Heart Failure with Preserved Ejection Fraction. Nature Reviews Cardiology. 17: 559–573. doi: 10.1038/s41569-020-0363-2
Bruno D.C.F., Donatti A., Martin M., Almeida V.S., Geraldis J.C., Oliveira F.S., Dogini D.B., Lopes-Cendes I. 2020. Circulating Nucleic Acids in the Plasma and Serum as Potential Biomarkers in Neurological Disorders. Brazilian Journal of Medical and Biological Research. 53(10): 9881. doi: 10.1590/1414-431x20209881
Han D.S.C., Ni M., Chan R.W.Y., Chan V.W.H., Lui K.O., Chiu R.W.K., Lo Y.M.D. 2020. The Biology of Cell-free DNA Fragmentation and the Roles of DNASE1, DNASE1L3, and DFFB. American Journal of Human Genetics. 106(2): 202–214. doi: 10.1016/j.ajhg.2020.01.008
Kurlianskaya E.K., Mrochek A.G., Denisevich T.L., Kaliadka M.G., Russkich I.I. 2020. The Prognostic Role of Biomarkers in Patients with Chronic Heart Failure. Kardiologiia. 60(1): 16–22. doi: 10.18087/cardio.2020.1.n882
Mattox A.K., Douville C., Wang Y., Popoli M., Ptak J., Silliman N. Dobbyn L., Schaefer J., Lu S., Pearlman A.H., Cohen J.D., Tie J., Gibbs P., Lahouel K., Bettegowda C., Hruban R.H., Tomasetti C., Jiang P., Chan K.C.A., Lo Y.M.D., Papadopoulos N., Kinzler K.W., Vogelstein B. 2023. The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer. Cancer Discovery. 13(10): 2166–2179. doi: 10.1158/2159-8290.CD-21-1252
Oellerich M., Schütz E., Beck J., Walson P.D. 2019. Circulating Cell-Free DNA-Diagnostic and Prognostic Applications in Personalized Cancer Therapy. Therapeutic Drug Monitoring. 41(2): 115–120. doi: 10.1097/FTD.0000000000000566
Polina I.A., Ilatovskaya D.V., DeLeon-Pennell K.Y. 2020. Cell free DNA as a Diagnostic and Prognostic Marker for Cardiovascular Diseases. Clinica Chimica Acta. 503: 145–150. doi: 10.1016/j.cca.2020.01.013
Roger V.L. 2021. Epidemiology of Heart Failure: A Contemporary Perspective. Circulation Research. 128(10): 1421–1434. doi: 10.1161/CIRCRESAHA.121.318172
Stejskal P., Goodarzi H., Srovnal J., Hajdúch M., van 't Veer L.J., Magbanua M.J.M. 2023. Circulating Tumor Nucleic Acids: Biology, Release Mechanisms, and Clinical Relevance. Molecular Cancer. 22(1): 15. doi: 10.1186/s12943-022-01710-w
Teo Y.V., Capri M., Morsiani C., Pizza G., Faria A.M.C., Franceschi C., Neretti N. 2019. Cell-free DNA as a Biomarker of Aging. Aging Cell. 18(1): 12890. doi: 10.1111/acel.12890
Wu B., Ni H., Li J., Zhuang X., Zhang J., Qi Z., Chen Q., Wen Z., Shi H., Luo X., Jin B. 2017. The Impact of Circulating Mitochondrial DNA on Cardiomyocyte Apoptosis and Myocardial Injury after TLR4 Activation in Experimental Autoimmune Myocarditis. Cellular Physiology and Biochemistry. 42(2): 713–728. doi: 10.1159/000477889
Yokokawa T., Misaka T., Kimishima Y., Shimizu T., Kaneshiro T., Takeishi Y. 2020. Clinical Significance of Circulating Cardiomyocyte-Specific Cell-Free DNA in Patients with Heart Failure: A Proof-of-Concept Study. Canadian Journal of Cardiology. 36(6): 931–935. doi: 10.1016/j.cjca.2019.10.016
The work was carried out without external sources of funding.